Skip to main content
Richard O'Reilly, MD, Pediatric Hematology & Oncology, New York, NY, Memorial Sloan Kettering Cancer Center

RichardJO'ReillyMD

Pediatric Hematology & Oncology • New York, NY

Attending, Department of Pediatrics

Request Appointment

Overview of Dr. O'Reilly

Dr. Richard O'Reilly is a pediatric hematologist/oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and NYC Health + Hospitals / Bellevue. He received his medical degree from University of Rochester School of Medicine and Dentistry and has been in practice 49 years. Dr. O'Reilly accepts several types of health insurance, listed below. He is one of 92 doctors at Memorial Sloan Kettering Cancer Center and one of 14 doctors at NYC Health + Hospitals / Bellevue who specialize in Pediatric Hematology & Oncology. He has more than 100 publications and over 500 citings.

Education & Training

  • Brigham and Women's Hospital
    Brigham and Women's HospitalResidency, Internal Medicine, 1971 - 1973
  • M Health Fairview
    M Health FairviewInternship, Transitional Year, 1968 - 1969
  • University of Rochester School of Medicine and Dentistry
    University of Rochester School of Medicine and DentistryClass of 1968

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 1973 - 2025
  • American Board of Pediatrics Pediatrics

Awards, Honors, & Recognition

  • Whos Who in Medicine and Healthcare Marquis Whos Who
  • Super Doctor SuperDoctors.com

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Allogeneic CD34-Selected HSCT Following CAR T-Cells Is Associated with Low TRM and Favorable OS in Pediatric/Young Adult Patients with Relapsed/Refractory B-ALL
    Richard O'Reilly, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

  • Double-Unit Cord Blood (CB) Transplantation with Haplo-Identical CD34+ Cells (haplo-dCBT) May Speed Neutrophil Recovery Although Successful Bridging Is Contingent on C... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Atara Biotherapeutics Announces Next-Generation CAR T Discoveries and Positive T-cell Immunotherapy Results in Patients with EBV+ PTLD Involving the CNS at 60th American Society of Hematology (ASH) Annual Meeting
    Atara Biotherapeutics Announces Next-Generation CAR T Discoveries and Positive T-cell Immunotherapy Results in Patients with EBV+ PTLD Involving the CNS at 60th American Society of Hematology (ASH) Annual MeetingDecember 3rd, 2018
  • Don't Miss Out!
    Don't Miss Out!November 1st, 2018
  • Shop Talk
    Shop TalkAugust 10th, 2016
  • Join now to see all

Grant Support

  • A Retrospective And Cross- Sectional Study Of Hematopoietic Cell TransplantationNational Institute Of Allergy And Infectious Diseases2011
  • EBV Specific T-Cells From 3rd Party Donors For Treatment Of Ebv-Associated MalignNational Cancer Institute2011
  • Development &Evaluation Of Practicable Approaches For Generation Of Cytotoxic &National Cancer Institute2007–2011
  • Clinical Trials Of Allogeneic Stem Cell Transplant In Lymphohematopoietic DisordeNational Cancer Institute2007–2011
  • The Immunobiology Of Marrow Allografts For LeukemiaNational Cancer Institute2002–2011
  • Artif. Antigen Presentation To Sensitize Virus-Spec. Tcells For Adoptive ImmunothNational Cancer Institute2006–2010
  • Project 5National Cancer Institute2005–2009
  • Molecular Targeting Of Developmental Cancers In ChildrenNational Cancer Institute2005–2009
  • Core DNational Cancer Institute2005–2009
  • Cellular Immunity Targeting Epithelial Ovarian CancerNational Cancer Institute2005–2009
  • IL-7 For Immune Recovery After Hematopoietic AllograftsNational Heart, Lung, And Blood Institute2001–2008
  • Administrative CoreNational Cancer Institute2007
  • T Cell Recognition Of Host Leukemia &Control Of CellsNational Cancer Institute2002
  • Core--Biostatistics CoreNational Cancer Institute2002
  • Clinical Trials Of Allogenic BMT / Stem Cell TransplantsNational Cancer Institute2002
  • T Lymphocytes For Treatment Of Ebv-Related LymphomaNational Cancer Institute2000–2002
  • Suicide Gene Modified EBV Antigen Sensitized T Cells For EBV Related LymphomaNational Cancer Institute1997–2001
  • Clinical Trials In Marrow TransplantationNational Cancer Institute1997–2001
  • Biology And Genetics Of Marrow Allografts For LeukemiaNational Cancer Institute1993–2001
  • Genetically Modified T Lymphocytes For Treatment Of Ebv-Related LymphomaNational Cancer Institute1997–1999
  • EBV B Cell Lymphomas And SCIDNational Heart, Lung, And Blood Institute1997
  • Experimental Approaches To Clinical TransplantationNational Cancer Institute1996
  • A Murine Model For Examining The Antileukemic Effect Of A Marrow AllograftNational Cancer Institute1996
  • EBV B Cell Lymphomas And SCID MiceNational Heart, Lung, And Blood Institute1994–1996
  • Cytokines In Genetic And Acquired Hemopoietic DisordersNational Institute Of Allergy And Infectious Diseases1991–1993
  • Marrow Transplantation In Leukemia And Other DiseasesNational Cancer Institute1988–1992
  • Marrow Transplant/Scid/Lethal Congenital ImmunodefiencyNational Cancer Institute1989–1990
  • Marrow Transp./Scid &Other Lethal Congenital Immunodef.National Cancer Institute1987–1988
  • Marrow Transplantation In Leukemia &Blood DiseasesNational Cancer Institute1985–1988
  • Transplantation Of Lethal Congenital ImmunodeficienciesNational Cancer Institute1985

Hospital Affiliations

Insurance Accepted

  • Aetna Choice POS II
    Aetna HMO
    Anthem Blue Access PPO
    Anthem Blue Preferred HMO
    BCBS Blue Card PPO
    BCBS Illinois PPO
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    Empire BCBS HMO
    Empire BCBS PPO
    GHI PPO
    Great West PPO
    HealthLink PPO
    Humana ChoiceCare Network PPO
    Multiplan PHCS PPO
    Multiplan PPO
    Oxford Health Freedom
    Oxford Health Liberty
    QualCare HMO
    QualCare PPO
    Sagamore Health Plus
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment

Dr. Richard O'Reilly, Dr. Richard O'Reilly, MD, Dr. R O'Reilly, Dr. Richard J O'Reilly